invest in semaglutide Novo Nordisk Investing $6 Billion to Increase Access to Ozempic, Wegovy Semaglutide Market Size, Share &

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that the GLP-1/GLP agonist at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

It takes four to five weekly doses to reach steady-state blood levels at any given dose

Oral medication kits and compounded GLP-1 injections are not available in all states

The medications' effect on gastric emptying and reduced caloric intake creates a sustained energy deficit, which triggers metabolic adaptations aimed at conserving energy

If you are using Ozempic for weight loss, your weekly dose helps regulate appetite